



LegeBioTech

Colon cancer, fourth in the world

THE PROBLEM


1,142,286 nuevos casos en 2022
Mortalidad del 47%

55%

Stages III and IV
People from 30 years old



We have more colon cancer in young people



OUR SOLUTION

Recombinant protein of natural origin rTBL-1:

Inhibits tumor growth **without causing systemic toxicity**



Molecular homology



In vitro mechanisms of action



Preclinical safety tests



Patent granted in Mexico (MX/a/2018/009442)

LEVEL OF DEVELOPMENT

TRL-3 technological maturity

- ✓ Starting Preclinical Trials
- ✓ Optimizing production

FOUNDING TEAM



Dra. Teresa García Gasca
Co-founder



Dr. Ulises Moreno Celis
Co-founder



Dr. Alejandro Blanco Labra
Strategic Advisor



Dr. Juan Joel Mosqueda
Scientific Advisor



Dr. Francisco Luján Méndez
Scientific Advisor



Dr. Roberto Esquivel García
CEO



Dra. Dulce Palmerín Carreño
Technical Advisor



Dr. Alberto Pastrana Palma
Business Advisor



Dr. Luis Alberto Ibarra
Technical Manager



Lic. Juan Trejo Vega
General Manager



Lic. Sara Escamilla Peña
Community Manager




Dr. Bruno de la Garza Trejo
Financial Advisor



Mtro. Alejandro Ramírez
Legal Adviser

MARKET



Market for adjuvant therapy in colon cancer.

INVESTMENT

Lifting Stage 1

\$1,230,587.50 USD

1. Scaling and formulation

19%

- ✓ Scale to 350 L
- ✓ Produce with GMP
- ✓ Develop pharmaceutical presentation

CAPEX: 2% computer/office equipment

2. Conclude GLP preclinical phase

62%

- ✓ Complete safety trials
- ✓ Conduct efficacy trials
- ✓ Conduct comparative trials

3. Regulatory process

9%

- ✓ Preparation of folders
- ✓ COFEPRIS evaluation

4. International patents

10%

- ✓ At least two patents
- ✓ EU registration
- ✓ European Community registration

Contact:
Francisco Lozano Martínez
flozano@newgenesis.cl

Raúl Vázquez Cassani
rvazquez@newgenesis.cl